

Sub B2 cont
A1
group consisting of C₃₋₈ hydrocarbon of a linear or branched configuration 2 - 10%, aqueous polar solvent 10-99%, and active compound 0.1-25%, or

where said active compound is soluble in a pharmacologically acceptable non-polar solvent said composition comprises in weight % of total composition: non-polar solvent 30-99.69%, active compound 0.005-55%, and

where said composition in a non-polar solvent additionally comprises a pharmaceutically acceptable propellant said composition comprises in weight % of total composition: a propellant selected from the group consisting of C₃₋₈ hydrocarbon of a linear or branched configuration 5-80%, non-polar solvent 20-85%, active compound 0.05-50%,

wherein the active compound is selected from the group consisting of biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostoglandins, bronchial dilators selected from the group consisting of terbutaline, and theophylline.

A2
6. (Amended) The composition of Claim 1 wherein the polar solvent is aqueous polyethylene glycol.

7. (Amended) The composition of Claim 1 wherein the polar solvent comprises aqueous ethanol.

8. (Amended) The composition of Claim 1 wherein the active compound is selected from the group consisting of cyclosporin, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, and valerian in their nonionized form or as the pharmaceutically acceptable salts thereof.

A3
11. (Amended) The composition of Claim 2 of the formulation: polar solvent 19-90%, ondansetron hydrochloride 2.5-15%, flavoring agent 1-10%.

12. (Amended) A method of administering a pharmacologically active compound